Emerging role of resveratrol in the treatment of severe acute pancreatitis.
Severe acute pancreatitis (SAP) develops in 15-20% of patients with acute pancreatitis. The management of SAP is a challenging task owing to the fact that it can lead to morbid conditions like multiple organ failure and systemic inflammatory response syndrome, if left untreated. Resveratrol, a drug used in Chinese traditional medicine has shown potential to treat many symptoms of SAP due to its multiple physiological actions. It possesses anti-inflammatory and anti-oxidative properties, both of which are essential in SAP. NF-kappaB activation is a major source of pro-inflammatory mediators in SAP. Administration of resveratrol can inhibit NF-kappaB activity as well as reduce the concentrations of TNF-alpha, IL-6 and IL-1. It can also scavenge reactive oxygen species that are capable of extensive tissue damage. Furthermore, resveratrol also exhibits anti-apoptotic properties via regulation of apoptotic mediators such as Bax, Bcl-2, and caspase-3. It also plays a role in calcium regulation and alleviates SAP-induced histopathological distortions in the pancreas. These multi-faceted results support the use of resveratrol in SAP and mandate the need for extensive research on this molecule.
Jha
Rajiv Kumar
RK
Department of Surgery, First Affiliated Hospital of Xi'an, Jiaotong University Xi'an 710061, China.
Ma
Qingyong
Q
Sha
Huanchen
H
Palikhe
Muna
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D019283:Pancreatitis, Acute Necrotizing / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; D017382:Reactive Oxygen Species; D013267:Stilbenes; D014409:Tumor Necrosis Factor-alpha; D051028:bcl-2-Associated X Protein; D053148:Caspase 3; D000077185:Resveratrol